|
1
|
Relf M, LeJeune S, Scott PA, Fox S, Smith
K, Leek R, Moghaddam A, Whitehouse R, Bicknell R and Harris AL:
Expression of the angiogenic factors vascular endothelial cell
growth factor, acidic and basic fibroblast growth factor, tumor
growth factor beta-1, platelet-derived endothelial cell growth
factor, placenta growth factor, and pleiotrophin in human primary
breast cancer and its relation to angiogenesis. Cancer Res.
57:963–969. 1997.
|
|
2
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis--correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weidner N, Folkman J, Pozza F, Bevilacqua
P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis:
a new significant and independent prognostic indicator in
early-stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fox SB, Leek RD, Bliss J, Mansi JL,
Gusterson B, Gatter KC and Harris AL: Association of tumor
angiogenesis with bone marrow micrometastases in breast cancer
patients. J Natl Cancer Inst. 89:1044–1049. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Uzzan B, Nicolas P, Cucherat M and Perret
GY: Microvessel density as a prognostic factor in women with breast
cancer: a systematic review of the literature and meta-analysis.
Cancer Res. 64:2941–2955. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guidi AJ, Fischer L, Harris JR and Schnitt
SJ: Microvessel density and distribution in ductal carcinoma in
situ of the breast. J Natl Cancer Inst. 86:614–619. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engels K, Fox SB, Whitehouse RM, Gatter KC
and Harris AL: Distinct angiogenic patterns are associated with
high-grade in situ ductal carcinomas of the breast. J Pathol.
181:207–212. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fox SB, Generali DG and Harris AL: Breast
tumour angiogenesis. Breast Cancer Res. 9:2162007. View Article : Google Scholar
|
|
9
|
Soncin F, Mattot V, Lionneton F, Spruyt N,
Lepretre F, Begue A and Stehelin D: VE-statin, an endothelial
repressor of smooth muscle cell migration. EMBO J. 22:5700–5711.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parker LH, Schmidt M, Jin SW, Gray AM,
Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, De
Sauvage FJ and Ye W: The endothelial-cell-derived secreted factor
Egfl7 regulates vascular tube formation. Nature. 428:754–758. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diaz R, Silva J, Garcia JM, Lorenzo Y,
Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F and
Dominguez G: Deregulated expression of miR-106a predicts survival
in human colon cancer patients. Genes Chromosomes Cancer.
47:794–802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu F, Yang LY, Li YF, Ou DP, Chen DP and
Fan C: Novel role for epidermal growth factor-like domain 7 in
metastasis of human hepatocellular carcinoma. Hepatology.
50:1839–1850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang CH, Li XJ, Zhou YZ, Luo Y, Li C and
Yuan XR: Expression and clinical significance of EGFL7 in malignant
glioma. J Cancer Res Clin Oncol. 136:1737–1743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caetano B, Drobecq H and Soncin F:
Expression and purification of recombinant vascular
endothelial-statin. Protein Expr Purif. 46:136–142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lelièvre E, Hinek A, Lupu F, Buquet C,
Soncin F and Mattot V: VE-statin/egfl7 regulates vascular
elastogenesis by interacting with lysyl oxidases. EMBO J.
27:1658–1670. 2008.PubMed/NCBI
|
|
16
|
Moll R, Mitze M, Frixen UH and Birchmeier
W: Differential loss of E-cadherin expression in infiltrating
ductal and lobular breast carcinomas. Am J Pathol. 143:1731–1742.
1993.PubMed/NCBI
|
|
17
|
Lee AH, Dublin EA, Bobrow LG and Poulsom
R: Invasive lobular and invasive ductal carcinoma of the breast
show distinct patterns of vascular endothelial growth factor
expression and angiogenesis. J Pathol. 185:394–401. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Delfortrie S, Pinte S, Mattot V, Samson C,
Villain G, Caetano B, Lauridant-Philippin G, Baranzelli M-C,
Bonneterre J, Trottein F, Faveeuw C and Soncin F: Egfl7 promotes
tumor escape from immunity by repressing endothelial cell
activation. Cancer Res. 71:7176–7186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmidt MH, Bicker F, Nikolic I, Meister
J, Babuke T, Picuric S, Muller-Esterl W, Plate KH and Dikic I:
Epidermal growth factor-like domain 7 (EGFL7) modulates Notch
signalling and affects neural stem cell renewal. Nat Cell Biol.
11:873–880. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parr C, Watkins G and Jiang WG: The
possible correlation of Notch-1 and Notch-2 with clinical outcome
and tumour clinicopathological parameters in human breast cancer.
Int J Mol Med. 14:779–786. 2004.PubMed/NCBI
|
|
21
|
Dickson BC, Mulligan AM, Zhang H, Lockwood
G, O’Malley FP, Egan SE and Reedijk M: High-level JAG1 mRNA and
protein predict poor outcome in breast cancer. Mod Pathol.
20:685–693. 2007. View Article : Google Scholar : PubMed/NCBI
|
